KU-55933 (ATM Kinase Inhibitor)

For research use only.

Catalog No.S1092

183 publications

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 110 In stock
EUR 68 In stock
EUR 117 In stock
EUR 363 In stock
EUR 930 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's KU-55933 (ATM Kinase Inhibitor) has been cited by 183 publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 NFrYfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHnNnRKSzVyPUOuNlc{PTJizszN MnvnV2FPT0WU
HuO-3N1 M{LrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C2OWlEPTB;ND6xO|E1OiEQvF2= NEPTXVZUSU6JRWK=
LAMA-84 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTRwNUi0OlUh|ryP MnG5V2FPT0WU
CAL-72 NUXHR5BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT4XlBkUUN3ME21MlQ5ODh2IN88US=> NX:y[oVKW0GQR1XS
LoVo MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwOUOyN|kh|ryP MkPnV2FPT0WU
HH NE\DSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRThwMke2O|Eh|ryP M3z0fnNCVkeHUh?=
SK-MEL-3 NH\wSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRThwMki1O|Uh|ryP NUWwT5NNW0GQR1XS
KM12 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHuRXNKSzVyPUmuNlEyPDJizszN M3TvXXNCVkeHUh?=
NCI-H1437 NFjTeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrJWmk3UUN3ME25MlgxQTdizszN NYXNU45mW0GQR1XS
NCI-H1838 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHwTWM2OD1zMT6xPFY2KM7:TR?= M3LRVXNCVkeHUh?=
J-RT3-T3-5 NUfVNlJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfybZRiUUN3ME2xNU4zPDF5IN88US=> NF\ic3VUSU6JRWK=
GOTO NGj6c4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFzLk[5PVYh|ryP MXHTRW5ITVJ?
LB2241-RCC NYLoWI1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M162R2lEPTB;MUGuO|E5PiEQvF2= M3TXUHNCVkeHUh?=
ES7 NFTYVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnzTWM2OD1zMT63PFgh|ryP MVLTRW5ITVJ?
KP-N-YS MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWyTIZKSzVyPUGyMlY{PTRizszN M{OzO3NCVkeHUh?=
CAL-12T NHrjfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF|Lk[xO{DPxE1? NWXETYdmW0GQR1XS
COLO-684 NVSxVFVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3LTWM2OD1zND6xOVY6KM7:TR?= MXHTRW5ITVJ?
DOK NHT0dJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HaN2lEPTB;MUWuN|MzQSEQvF2= MYrTRW5ITVJ?
Hs-578-T NW\PPVJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDJVFBKSzVyPUG1MlQyQDJizszN MYHTRW5ITVJ?
D-423MG Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ezRmlEPTB;MUWuOVI{PiEQvF2= MoLqV2FPT0WU
DBTRG-05MG MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PtVWlEPTB;MUWuOlEyOSEQvF2= NXTUcW96W0GQR1XS
VM-CUB-1 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PuZWlEPTB;MUWuPVg1QSEQvF2= M2nZUHNCVkeHUh?=
KG-1 NH;KW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PJRmlEPTB;MU[uNFk6PiEQvF2= MULTRW5ITVJ?
8305C NHrFXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF4LkG4PFkh|ryP NEfiVGNUSU6JRWK=
HuH-7 M2n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[3O5lKSzVyPUG2MlI3PzRizszN MmXNV2FPT0WU
LXF-289 NVTBVIpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF4LkK3OFch|ryP MmH0V2FPT0WU
NCI-H1793 NHHvWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTocYlQUUN3ME2xOk41PzF{IN88US=> NWXwclBEW0GQR1XS
ChaGo-K-1 NELKfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrRTWM2OD1zNj62OVY5KM7:TR?= MV7TRW5ITVJ?
GCIY M3XQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjkTWM2OD1zNj63PVA2KM7:TR?= MWPTRW5ITVJ?
SK-MEL-28 NFXVN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7rTWM2OD1zNz6wOFc2KM7:TR?= NHfYOpNUSU6JRWK=
NCI-SNU-1 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnCWXlKSzVyPUG3MlEzPjlizszN MVrTRW5ITVJ?
CTB-1 M4nwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DtdGlEPTB;MUeuNlI2QSEQvF2= MYTTRW5ITVJ?
NCI-H82 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX5PYhDUUN3ME2xO{41PTd|IN88US=> NXX5U2diW0GQR1XS
HCC2998 MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[4cmlEPTB;MUeuOlc{OyEQvF2= NHL3cmpUSU6JRWK=
NCI-H2030 MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF6LkG5PVch|ryP NW[5e|hIW0GQR1XS
HuP-T3 NFG2cIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5TWM2OD1zOD61PFg5KM7:TR?= MXXTRW5ITVJ?
697 NG\Se|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\2N2ZKSzVyPUG5MlAzODFizszN NG\HelVUSU6JRWK=
MLMA M{i1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzn[XVKSzVyPUG5MlA2PTdizszN Mmi0V2FPT0WU
HCC70 NXTnTJVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG1TWM2OD1zOT60PFkh|ryP MXfTRW5ITVJ?
A704 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37yeWlEPTB;MUmuPFMxPSEQvF2= NVXCN3hDW0GQR1XS
D-283MED MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf5O5lKSzVyPUKwMlU{OzlizszN M{LXcnNCVkeHUh?=
U031 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Ydo5kUUN3ME2yNU4yPDh7IN88US=> NIizVYdUSU6JRWK=
HSC-3 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHRfpdKSzVyPUKxMlE5OzVizszN MmjMV2FPT0WU
JVM-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHRNIplUUN3ME2yNk42ODZizszN NUHx[XA4W0GQR1XS
Mewo MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\LT2lEPTB;MkKuOVA4OyEQvF2= MkfQV2FPT0WU
YH-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jBOWlEPTB;MkKuOVEzOyEQvF2= NWXxcndpW0GQR1XS
LB1047-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HCdGlEPTB;MkKuOVg4QSEQvF2= NXvI[Yh4W0GQR1XS
HCC2157 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ{LkiwOVQh|ryP Mlr1V2FPT0WU
SNU-449 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\STWM2OD1{Mj64O|Q5KM7:TR?= NH;DVIRUSU6JRWK=
Ramos-2G6-4C10 NF73NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjKN4xKSzVyPUKyMlk3KM7:TR?= NVXNVGd5W0GQR1XS
CHL-1 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zVW2lEPTB;MkOuO|I6OiEQvF2= MljuV2FPT0WU
SK-MEL-30 NEC5TJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvMdnBKSzVyPUK0MlQ3PjJizszN MXvTRW5ITVJ?
PANC-08-13 NVPOSod6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLnTWM2OD1{NT6wPVM5KM7:TR?= M{[2WnNCVkeHUh?=
QIMR-WIL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjoTWM2OD1{NT6xPFU5KM7:TR?= NHrNNo5USU6JRWK=
BFTC-905 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;lT4JKSzVyPUK1MlU6PDRizszN MkfTV2FPT0WU
GI-1 NUL0O|JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvJRlNKSzVyPUK1MlcxPTVizszN MWPTRW5ITVJ?
MDA-MB-415 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJ4LkWwN|Mh|ryP MWjTRW5ITVJ?
GT3TKB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr1TWM2OD1{Nj61N|QzKM7:TR?= MoDSV2FPT0WU
DEL M3rubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjLTWM2OD1{Nj64N|U3KM7:TR?= M132WnNCVkeHUh?=
KOSC-2 NYPGNpBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjPTWM2OD1{Nj65NFc2KM7:TR?= NH72WpZUSU6JRWK=
RVH-421 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHEdpdKSzVyPUK3MlI6OjFizszN NHjIfpVUSU6JRWK=
EW-13 MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj0XYdKSzVyPUK3MlQ{ODhizszN NWXpfm42W0GQR1XS
639-V Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJ5LkWxNVkh|ryP M3THVXNCVkeHUh?=
A2780 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\PSmlEPTB;MkeuOlQyKM7:TR?= NVXj[WdtW0GQR1XS
SW982 NGXufY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTycYlLUUN3ME2yO{46ODV{IN88US=> MYDTRW5ITVJ?
SW1710 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT6TWM2OD1{OD6wPVgyKM7:TR?= NVPJW3F3W0GQR1XS
HCC1569 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ6LkS4PVch|ryP NIDpPI1USU6JRWK=
MV-4-11 NVXSOY1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL4VYZKSzVyPUK4MlU4OzVizszN NWf6WJU{W0GQR1XS
BHT-101 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXCTWM2OD1{OD62OVczKM7:TR?= MkL3V2FPT0WU
Ca9-22 M{fUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rqS2lEPTB;MkiuO|E1KM7:TR?= NHLzdWtUSU6JRWK=
HAL-01 NXvMVVl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmySYlJUUN3ME2yPE44PjF3IN88US=> NWjX[5lFW0GQR1XS
D-263MG NEDLclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4niWWlEPTB;MkmuN|Q1KM7:TR?= MYrTRW5ITVJ?
NEC8 NFXsfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJ7LkW1OFgh|ryP MWTTRW5ITVJ?
EKVX Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNzLkW4OFch|ryP MWPTRW5ITVJ?
EM-2 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTyTWM2OD1|MT62N|A1KM7:TR?= NHzWV4tUSU6JRWK=
MFM-223 NUjLPVk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDTU2dKSzVyPUOxMlgxQThizszN NY[4SVlpW0GQR1XS
SK-PN-DW NXG4VXRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjJXINKSzVyPUOyMlE1ODZizszN Ml23V2FPT0WU
HuO9 NFq2XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HCTWlEPTB;M{KuOVI5OiEQvF2= NUXITJJEW0GQR1XS
MHH-PREB-1 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvqWlhKSzVyPUOyMlYzOzRizszN NEXu[phUSU6JRWK=
OVCAR-4 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHBTWM2OD1|Mj64N|Y{KM7:TR?= MoHXV2FPT0WU
NCI-H1648 NVPYXYg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr0NY5qUUN3ME2zNk45PjVzIN88US=> MYDTRW5ITVJ?
MKN1 NWDPcXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLzeWZqUUN3ME2zOE4yOTBzIN88US=> MYLTRW5ITVJ?
KYSE-450 MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInoOmJKSzVyPUO0MlY1PDRizszN MVrTRW5ITVJ?
ES8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjYVVZ{UUN3ME2zOE45QTd3IN88US=> NH3zUmJUSU6JRWK=
MS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTWVJVuUUN3ME2zOE46PTV2IN88US=> NGn4eHdUSU6JRWK=
HOP-92 M3Xpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHsfVNKSzVyPUO1MlkzPzdizszN NWi5enVCW0GQR1XS
SKG-IIIa M4PO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfvcYVKUUN3ME2zOk4zPTZzIN88US=> NUnJcHo3W0GQR1XS
TE-11 NHT3[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTN4LkWyOFMh|ryP M1uz[XNCVkeHUh?=
SK-NEP-1 NWDwWXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljLTWM2OD1|Nz62O|Q1KM7:TR?= MVfTRW5ITVJ?
DB Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrUTWM2OD1|Nz65NVg2KM7:TR?= M{m1SnNCVkeHUh?=
IA-LM NWjjUoxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXjbmo1UUN3ME2zPE4xOjN7IN88US=> MnPjV2FPT0WU
COLO-829 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW1NnlKSzVyPUO4MlQyPTlizszN MWTTRW5ITVJ?
TGBC11TKB NEPvbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHsTWM2OD1|OT6xOFA5KM7:TR?= NHjSbHJUSU6JRWK=
CAL-51 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SycGlEPTB;NECuNFYyOiEQvF2= NXW2V2FOW0GQR1XS
NCI-H2228 NXW4O2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXldJdLUUN3ME20NE4{PjZ{IN88US=> NGfWfVVUSU6JRWK=
C32 NUTMdHdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr1TWM2OD12MD60NFI1KM7:TR?= NYr3VJZ1W0GQR1XS
KU-19-19 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfjSXZKSzVyPUSwMlc3QDNizszN NXnSdmJUW0GQR1XS
KNS-62 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRyLkizPFEh|ryP MnS1V2FPT0WU
FADU NGDRfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK4[JBKSzVyPUSxMlI2ODJizszN MnLJV2FPT0WU
CAL-33 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTR{Lk[3OFkh|ryP MVnTRW5ITVJ?
CHP-134 NHO4VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTmTWM2OD12Mj64OFk3KM7:TR?= NIjVN2JUSU6JRWK=
HDLM-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTR{LkmwPFQh|ryP MluzV2FPT0WU
NBsusSR MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Hd2lEPTB;NEOuNFczPSEQvF2= NXfmOYoyW0GQR1XS
SW954 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTR|LkGwOVMh|ryP NWjNRnBPW0GQR1XS
HCC1806 NFnnclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDBUm9KSzVyPUSzMlQyOSEQvF2= MX3TRW5ITVJ?
VMRC-RCZ MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTR|LkS1PFYh|ryP NHvkc|RUSU6JRWK=
A549 NXjKc3JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPkTWM2OD12Mz65N|Eh|ryP MYPTRW5ITVJ?
NKM-1 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjLOVRKSzVyPUSzMlk2PThizszN NGDRVVFUSU6JRWK=
DMS-273 M2PZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS2ZVBKSzVyPUS0Mlc2PjdizszN M4f4OHNCVkeHUh?=
TYK-nu MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SzTWlEPTB;NEWuNVI{PCEQvF2= NWLMTlRYW0GQR1XS
KALS-1 M{DXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PmUGlEPTB;NEWuNVQ3KM7:TR?= NFPTPJBUSU6JRWK=
A101D Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTFTWM2OD12NT60OFU3KM7:TR?= M1XUfnNCVkeHUh?=
G-361 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR4LkKxN|gh|ryP MWPTRW5ITVJ?
KARPAS-299 NF;6V4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID5ZVNKSzVyPUS2MlM2OTZizszN MV3TRW5ITVJ?
RS4-11 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTR4LkW0NkDPxE1? NETMblhUSU6JRWK=
HT-1376 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR4Lke0NlYh|ryP MX7TRW5ITVJ?
SK-N-AS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vifWlEPTB;NE[uO|gzOiEQvF2= NXPHNYhpW0GQR1XS
MG-63 NEXiSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XiOWlEPTB;NE[uPVA{PiEQvF2= MYDTRW5ITVJ?
EPLC-272H NH7wcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DKUmlEPTB;NE[uPVUxOyEQvF2= NHft[5pUSU6JRWK=
BALL-1 MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\FOXRzUUN3ME20O{45OzJizszN MXvTRW5ITVJ?
LCLC-97TM1 M3XZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzmXXN3UUN3ME20PE4zODJizszN NE\F[WpUSU6JRWK=
HO-1-N-1 NFHL[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjKc5FkUUN3ME20PE46Pjd4IN88US=> MVnTRW5ITVJ?
MFE-280 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHRTWM2OD12OT60OlE4KM7:TR?= MVjTRW5ITVJ?
NCI-H526 NF7ZbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfV[HZKSzVyPUS5MlgyPjNizszN NFXuOFNUSU6JRWK=
D-566MG NVLpc444T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGycnZSUUN3ME20PU46ODl4IN88US=> NGro[HNUSU6JRWK=
BB30-HNC NF\IUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknYTWM2OD12OT65OFk5KM7:TR?= M{PmPXNCVkeHUh?=
SK-N-DZ NY\HcYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTYTWM2OD13MD6wOFgyKM7:TR?= NWHsSmdJW0GQR1XS
HepG2  MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fkT|ExyqEQvF2= MUSyOEBp M4LB[oJtd2OtczDTR{1KUUl|LXnu[JVk\WRiUzDwbIF{\SCjcoLld5Q> NIjp[|UzPTV{N{GyNy=>
HepG2  NGmxOm1HfW6ldHnvckBCe3OjeR?= MWWxNOKh|ryP NH7ZN5AzPCCq MUTzeZBxemW|c3XzJJRp\SCyaH;zdIhwenmuYYTpc45{KG:oIFHUUUBwdiCVZYKxPVgyNCCFaHuxJI9vKFOnckO0OUwhS2itMjDvckBVcHJ4ODygZY5lKEOma{Kgc44hXHm{MUWgbY5lfWOnZDDifUBUSy2LSVmz NV;od25jOjV3MkexNlM>
KATO III  NEXTb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\0ZVIvPS93L{euOUDPxE1? NYnMOW9iTE2VTx?= NXjob2FL\W6qYX7j[ZMhfGinIITvfIlkcXS7IH;mJI9t[XCjcnni MWCyOFg1OTdzOB?=
hTCEpi MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL2NncyOCEQvF2= MmHRSG1UVw>? NI\0bJJxemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF? NWnSVYg2OjR|N{C4N|U>
MCF10A MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L0dFExKM7:TR?= NXyxVGV6OjRiaB?= NXzscJJFTE2VTx?= M1jBXZBwfGWwdHnheIV{KHSqZTDjfZRwfG:6aXPpeJkhd2ZiR1G= M175NlI1OTVyNUm1
HL-60  NUfzdXN7TnWwY4Tpc44hSXO|YYm= M{HUe|ExKM7:TR?= M372VVAvPSCq MkjpSG1UVw>? M4Xjd5Jm\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczMEoB?= NF3OXnozOzl|NESxNS=>
MCF-7 NXzFfYpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTzWZkyNTFyMN88US=> NVvFSJU3OjRiaB?= NUHKXY9UTkKV NETL[5ZqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NWHZS|Z[OjNzOEWzOFc>
HeLa  M4TTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKxMVExOM7:TR?= NGfnfYYzPCCq NXPNXnl{TkKV NH7lSpRqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NHvXbYUzOzF6NUO0Oy=>
SH-SY5Y NXfuXYJKTnWwY4Tpc44hSXO|YYm= MYSxNOKh|ryPwrC= NELJ[4MzPCCq NIjCTlJqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= M{PiXFIzPjJ5Mkm0
IMR-32 MlK4SpVv[3Srb36gRZN{[Xl? NW\Zc3VuOTEEoN88UeKh NF\kZXMzPCCq NVvmOVhvcW6qaXLpeJMh[2yrb4H1bY5wdC2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCyNUO= M3HBelIzPjJ5Mkm0
A549 NXzR[|QyTnWwY4Tpc44hSXO|YYm= NVjKe|ZZOTEEoN88UeKh NH\GbYMyKGh? M{DRZZN2eHC{ZYPz[ZMhVmGwbz3Dc{1qdmS3Y3XkJJA2OyCjY3P1cZVt[XSrb36= MV2yNlU2QTN{MR?=
T47D  M1jvTmZ2dmO2aX;uJGF{e2G7 M4DV[|IxyqCvTR?= M1fnSVI1KGh? MnnESG1UVw>? Ml:2dJJmfmWwdIOgTXIucW6mdXPl[EBl\We{YXTheIlwdiCxZjDJ{tpD|rF? M3HDUlIyOTR2OEC1
A29 MEF MXjGeY5kfGmxbjDBd5NigQ>? Mlu2NVDDqM7:TdMg NGXyOZcycA>? MnTNZoxw[2u|wrD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGtdDDheEBU\XJ2N{RCpC=> NXjjT|c6OjByNUO3PFE>
MDA-MB-453  MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKyPYg2NTRyIN88US=> MYG3NkBp NHLxUIJKSzVyIH;mJFExKM7:TR?= M{LPclIxODV|N{ix
PC-3 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzIOU01OCEQvF2= M1L2UFczKGh? NWPrcIdEUUN3MDDv[kAyOCEQvF2= NXTjU4FvOjByNUO3PFE>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

- Collapse
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
3.95 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A
Smiles C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID